NYSE:NNVC NanoViricides (NNVC) Stock Price, News & Analysis $1.31 -0.01 (-0.76%) Closing price 10/14/2026 04:00 PM EasternExtended Trading$1.29 -0.02 (-1.45%) As of 07:46 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsFinancialsNews and TrendsOptions ChainOwnershipSEC Filings About NanoViricides Stock (NYSE:NNVC) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get NanoViricides alerts:Sign Up Key Stats Today's Range$1.28▼$1.3450-Day Range$1.02▼$1.6952-Week Range$0.85▼$2.23Volume150,061 shsAverage Volume528,014 shsMarket Capitalization$33.44 millionP/E RatioN/ADividend YieldN/APrice Target$6.00Consensus RatingBuy Company Overview NanoViricides, Inc. is a biotechnology company focused on developing antiviral therapies based on its proprietary nanomedicine platform. The company designs polymeric nanoviricide drug candidates intended to mimic cellular receptors, bind to viruses, and help remove them from circulation before they can infect healthy cells. The company’s research programs have addressed a range of viral diseases, including respiratory infections, influenza, herpesvirus infections, and other conditions for which improved antiviral treatments may be needed. Its product candidates are in various stages of preclinical and clinical development, and the company’s programs and priorities may change as research results become available. NanoViricides is headquartered in Shelton, Connecticut, and has historically focused on developing treatments for viral diseases affecting patients in global markets. The company was established in the mid-2000s. Anil R. Diwan has served as the company’s chairman and president and has been closely associated with its nanoviricide technology and corporate development.AI Generated. May Contain Errors. Read More NanoViricides Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks34th Percentile Overall ScoreNNVC MarketRank™: 1.69077995528 of 5 starsNanoViricides scored higher than 34% of companies evaluated by MarketBeat, and ranked 754th out of 873 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingNanoViricides has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on no strong buy ratings, 2 buy ratings, no hold ratings, and no sell ratings.Upside PotentialNanoViricides has a consensus price target of $6.00, representing about 358.0% upside from its current price of $1.31.Amount of Analyst CoverageNanoViricides has received no research coverage in the past 90 days.Read more about NanoViricides' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of NanoViricides is -1.82, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of NanoViricides is -1.82, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioNanoViricides has a P/B Ratio of 1.98. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for NNVC. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldNanoViricides does not currently pay a dividend.Dividend GrowthNanoViricides does not have a long track record of dividend growth. News and Social Media2.7 / 5News SentimentN/A News SentimentNanoViricides has a news sentiment score of 0.37. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.71 average news sentiment score of Healthcare companies.Search Interest32 people have searched for NNVC on MarketBeat in the last 30 days. This is an increase of 967% compared to the previous 30 days.MarketBeat Follows11 people have added NanoViricides to their MarketBeat watchlist in the last 30 days. This is an increase of 120% compared to the previous 30 days. Company Ownership0.3 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, NanoViricides insiders have not sold or bought any company stock.Percentage Held by Insiders3.60% of the stock of NanoViricides is held by insiders.Percentage Held by Institutions10.30% of the stock of NanoViricides is held by institutions.Read more about NanoViricides' insider trading history. Receive NNVC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for NanoViricides and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. NNVC Stock News HeadlinesNanoViricides (NYSE:NNVC) Shares Down 3.4% - Time to Sell?October 7, 2026 | americanbankingnews.comNanoViricides Provides Additional Details on the Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola as the Outbreak Continues to Expand and Has Taken Over ...October 5, 2026 | theglobeandmail.comReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and stinging losses? Dave Aquino is giving away the exact 11-hour options strategy he uses in volatile markets. You get the plain English blueprint behind the strategy and the very same "rinse and repeat" ticker he's traded nearly 900 times with a 95.3% success rate. It's so simple to understand, you could trade it tomorrow.October 15 at 1:00 AM | Base Camp Trading (Ad)Clinical Trial of the Oral Drug NV-387 to Treat Ebola Has Started Enrollment and Dosing of Patients Last Week, Says NanoViricidesSeptember 29, 2026 | marketscreener.comMClinical Trial of the Oral Drug NV-387 to Treat Ebola to Start Next Week, Hoping to Reduce Fatalities and Spread, As the Largest Ebola Outbreak is Expanding in DR Congo with 48 ...September 15, 2026 | finance.yahoo.comEbola Oral Drug Trial NV-387 Registered in DRC for OutbreakSeptember 8, 2026 | usatoday.comClinical Trial for an Oral Drug to Treat Ebola is Registered in the Pan African Clinical Trials Database and is Ready to Go, As the Largest Ebola Outbreak Continues to Expand ...September 8, 2026 | finance.yahoo.comWhile Measles Cases Continue to Increase in The USA and Globally, NanoViricides is Getting Ready for Clinical Trials of Its Revolutionary Broad-spectrum Drug Candidate NV-387 ...August 31, 2026 | usatoday.comSee More Headlines NNVC Stock Analysis - Frequently Asked Questions How have NNVC shares performed this year? NanoViricides' stock was trading at $1.13 at the start of the year. Since then, NNVC shares have increased by 15.9% and is now trading at $1.31. How were NanoViricides' earnings last quarter? NanoViricides, Inc. (NYSE:NNVC) issued its quarterly earnings data on Friday, September, 27th. The company reported ($0.19) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.20) by $0.01. When did NanoViricides' stock split? NanoViricides shares reverse split on Tuesday, September 24th 2019.The 1-20 reverse split was announced on Thursday, September 12th 2019. The number of shares owned by shareholders was adjusted after the market closes on Monday, September 23rd 2019. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. How do I buy shares of NanoViricides? Shares of NNVC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of NanoViricides own? Based on aggregate information from My MarketBeat watchlists, some other companies that NanoViricides investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Micron Technology (MU), Intel (INTC), Palantir Technologies (PLTR), Taiwan Semiconductor Manufacturing (TSM) and Inovio Pharmaceuticals (INO). Company Calendar Last Earnings9/27/2024Today10/14/2026Fiscal Year End6/30/2027Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (4w+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 For the last 4 weeks, NNVC's financial health has been in the Green zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNYSE SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNYSE:NNVC CIK1379006 Webwww.nanoviricides.com Phone(203) 668-5580Fax203-859-5095Employees7Year Founded2005Price Target and Rating Average Price Target for NanoViricides$6.00 High Price Target$6.00 Low Price Target$6.00 Potential Upside/Downside+358.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Trailing Twelve Months)($0.40) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$8.29 million Net MarginsN/A Pretax MarginN/A Return on Equity-87.90% Return on Assets-78.69% Debt Debt-to-Equity RatioN/A Current Ratio3.44 Quick Ratio2.47 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.66 per share Price / Book1.98Miscellaneous Outstanding Shares25,525,000Free Float14,922,000Market Cap$33.44 million OptionableOptionable Beta1.79 Social Links 7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free Report This page (NYSE:NNVC) was last updated on 10/14/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...Chaikin Analytics | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredBank of America: 'Digital Dollar Inevitable'Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the...Decentralized Masters | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NanoViricides, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share NanoViricides With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
